Overview

Study of Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inclisiran in Chinese Participants With Elevated Serum LDL-C

Status:
Active, not recruiting
Trial end date:
2021-12-09
Target enrollment:
Participant gender:
Summary
Study to evaluate the pharmacokinetics and pharmacodynamics of inclisiran treatment given as single subcutaneous injection in Chinese participants with elevated low-density lipoprotein cholesterol (LDL-C) despite treatment with LDL-C lowering therapies
Phase:
Phase 1
Details
Lead Sponsor:
Novartis Pharmaceuticals